翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 歌禮製藥有限公司 呈交日期： 2025年9月23日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | | 是 | | | 證券代號 (如上市) 01672 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | 已發行股份總數 | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件 ...

Market Performance - The Hang Seng Healthcare Index decreased by 2.62% as of September 23, 2025, with mixed performance among constituent stocks [3] - The Hang Seng Innovation Drug Selection Index fell by 2.68%, with notable gainers and losers among its components [5] - The CSI Pharmaceutical 50 Index dropped by 2.86%, with significant declines in several major pharmaceutical companies [7] ETF Performance - The Hang Seng Healthcare ETF (513060) declined by 2.31%, with a recent price of 0.72 yuan and a one-month cumulative increase of 1.94% [3] - The Hong Kong Innovation Drug Selection ETF (520690) decreased by 2.23%, with a recent price of 1.01 yuan and a cumulative increase of 4.56% since inception [5] - The Pharmaceutical 50 ETF (159838) fell by 2.60%, with a recent price of 0.64 yuan and a one-month cumulative increase of 2.51% [7] Liquidity and Trading Activity - The Hang Seng Healthcare ETF had a turnover of 15.25% and a trading volume of 1.119 billion yuan, indicating active market participation [3] - The Hong Kong Innovation Drug Selection ETF recorded a turnover of 17.52% and a trading volume of 70.328 million yuan [5] - The Pharmaceutical 50 ETF had a turnover of 1.32% and a trading volume of 2.1296 million yuan [7] Industry Developments - Pfizer plans to acquire Metsera for up to $7.3 billion, focusing on obesity treatment through innovative drug delivery methods [8] - Songlei Pharmaceutical reported promising Phase I clinical data for ASC47 combined with semaglutide, showing a 56.2% improvement in weight loss compared to semaglutide alone [8] - The obesity treatment sector is experiencing growth driven by mergers and technological advancements, with domestic companies also making significant progress [9] ETF Fund Flows - The Hang Seng Healthcare ETF has seen stable fund inflows, accumulating 188 million yuan over the last five trading days [9] - The Hong Kong Innovation Drug Selection ETF has maintained balanced fund flows, with a total of 38.2834 million yuan in net inflows over the past five trading days [10] - The Pharmaceutical 50 ETF's fund flows reflect a focus on large-cap pharmaceutical companies, with the top ten stocks comprising a significant portion of the index [11]

Major Events - Different Group (06090) has a public offering with a subscription rate of 3317.47 times the upper limit price [1] - Botai Che Lian (02889) plans to globally offer 10.4369 million H-shares from September 22 to September 25 [1] - Changhong Jiahua (03991) received a privatization offer from Changhong Group at a premium of approximately 32.93%, with resumption of trading on September 23 [1] - Huajian Medical (01931) signed a strategic cooperation agreement with Chuangsheng Group-B (06628) involving the tokenization of a $1.5 billion innovative drug pipeline asset [1] - Gilead Sciences-B (01672) reported that ASC47 combined with Semaglutide showed a weight loss effect improvement of up to 56.2% compared to Semaglutide alone in obese subjects [1] - Fosen Pharmaceutical (01652) plans to sell all equity of Henan Fosen Smart Energy Technology for 73 million yuan [1] - Maiyue Technology (02501) entered into strategic cooperation agreements with NetEase Youdao and Ferry International [1] - Zhongchuang Zhiling (00564) intends to invest 270 million yuan to establish Yaxinke Thermal Management Technology (Yizheng) Co., Ltd. to enhance market competitiveness in automotive thermal management systems [1] - Garmin Group Holdings (01271) plans to sell a portfolio of four data center projects for 5.25 billion HKD [1] Buybacks and Increases - Tencent Holdings (00700) repurchased 862,000 shares for 550 million HKD on September 22 [1] - Standard Chartered Group (02888) repurchased 517,100 shares for 7.3877 million GBP on September 19 [1] - Midea Group (00300) repurchased 3.415 million A-shares for 250 million yuan on September 22 [1] - Anta Sports (02020) repurchased 2.12 million shares for 199 million HKD on September 22 [1] - Kuaishou-W (01024) repurchased 1 million shares for 73.7998 million HKD on September 22 [1] - Heng Rui Pharmaceutical (01276) repurchased 656,000 A-shares for 45.7493 million yuan on September 19 [1] - Shenzhen Expressway Company (00548) received an increase of 25.38 million H-shares from shareholder Yunsong Capital [1]

港股三大指数全天水下震荡，盘中跌幅均一度扩大逾1%。截止收盘，恒生指数跌0.76%或200.96点，报 26344.14点，全日成交额为2905.37亿港元；恒生国企指数跌1.07%，报9370.73点；恒生科技指数跌 0.58%，报6257.91点。 东吴证券认为，港股仍在震荡上行趋势中，下行有底。该行指出，美联储降息靴子落地，港股上涨更取 决于产业景气度和基本面边际变化；当前外资对中国资产感兴趣的越来越多，但资金流入还处于早期阶 段；当前港股仍是结构性行情，建议自下而上寻相对低估的个股。 蓝筹股表现 中芯国际(00981)再创新高。截至收盘，涨5.16%，报73.35港元，成交额98.78亿港元，贡献恒指25.48 点。高盛近日指出，将中芯国际H股目标价上调15%至73.1港元。这一乐观预期主要源于对中国IC设计 需求和人工智能趋势的看好，预计这将强劲支撑中芯国际的产量与平均售价。该行同时上调公司2028- 2029年营收及每股收益预测，并指出2025年第三季度营收环比预计增长5%–7%，可能成为短期股价催 化剂。 4. 钢铁股表现活跃。截至收盘，马鞍山钢铁股份(00323)涨4.44%，报2.59港元； ...

Group 1 - The pharmaceutical stocks have generally risen, with notable increases in companies such as WuXi AppTec (6.82% increase), Innovent Biologics (5.72% increase), and WuXi Biologics (3.86% increase) [1] - The National Healthcare Security Administration has released the 11th batch of centralized procurement documents for drugs, emphasizing principles such as "stabilizing clinical use, ensuring quality, preventing collusion, and countering internal competition" [1] - The optimization of price control benchmarks in the procurement process indicates a shift away from simply selecting the lowest bid, reflecting a proactive approach by the healthcare authority to improve the domestic market [1] Group 2 - Guojin Securities expresses strong confidence in a reversal trend for the pharmaceutical sector in 2025, highlighting innovative drugs and the recovery of left-behind sectors as significant investment opportunities [2] - The upward trend in the innovative drug industry remains intact, with multinational corporations facing patent cliffs and likely to continue using business development strategies to fill revenue gaps [2] - Dongwu Securities notes that the easing interest rate environment is expected to enhance the prosperity of the innovative industry chain, benefiting upstream biotech and CXO sectors [2]

每经AI快讯，9月22日，港股医药股多数上扬。截至发稿，药明合联(02268.HK)涨6.82%，报75.2港元； 诺诚健华(09969.HK)涨5.72%，报17.38港元；药明生物(02269.HK)涨3.86%，报39.24港元；歌礼制药- B(01672.HK)涨3.09%，报11.01港元；恒瑞医药(01276.HK)涨2.74%，报90港元。 ...

Group 1 - The pharmaceutical stocks are mostly rising, with notable increases in companies such as WuXi AppTec (02268) up 6.82% to HKD 75.2, Innovent Biologics (09969) up 5.72% to HKD 17.38, and WuXi Biologics (02269) up 3.86% to HKD 39.24 [1] - The National Healthcare Security Administration has released the 11th batch of centralized procurement documents for drugs, emphasizing principles such as "stabilizing clinical use, ensuring quality, preventing collusion, and countering internal competition" [1] - The procurement plan optimizes the selection of price control "anchors," moving away from simply choosing the lowest bid, which reflects a proactive approach by the healthcare authority to promote a healthier domestic market [1] Group 2 - Guojin Securities expresses strong confidence in a reversal trend for the pharmaceutical sector in 2025, identifying innovative drugs and the left-side sector's recovery as the biggest investment opportunities [2] - The upward trend in the innovative drug industry remains unchanged, with multinational corporations facing patent cliffs and likely to continue using business development (BD) strategies to fill revenue gaps [2] - Dongwu Securities notes that in a context of interest rate cuts, the innovative industry chain's prosperity is expected to improve, benefiting upstream biotech and CXO sectors [2]

Core Viewpoint - The stock of Gilead Sciences-B (01672) increased by over 8%, reaching HKD 11.57 with a trading volume of HKD 23.73 million, following the announcement of significant clinical trial results for its weight loss drug ASC47 combined with semaglutide [1] Group 1: Clinical Trial Results - Gilead announced that in a study conducted on obese participants (BMI ≥ 30 kg/m²), the combination of ASC47 and semaglutide showed a weight loss effect that was 56.2% greater compared to the placebo combined with semaglutide [1] Group 2: Future Research Implications - The CEO of Gilead, Wu Jinzi, stated that this research provides important concept validation data, which will serve as a critical basis for the design of subsequent Phase IIb combination therapy studies targeting various metabolic diseases, including obesity and metabolic-associated fatty liver disease (MASH) [1]

Core Viewpoint - The stock of Gilead Sciences-B (01672) increased by over 8%, reaching HKD 11.57, with a trading volume of HKD 23.73 million, following the announcement of significant weight loss results from its candidate drug ASC47 in combination with semaglutide [1] Group 1: Company Announcement - Gilead Sciences announced that, on day 29, the weight loss effect of ASC47 combined with semaglutide in obese subjects (BMI ≥ 30 kg/m²) was enhanced by up to 56.2% compared to the placebo combined with semaglutide [1] - The founder, chairman, and CEO of Gilead Sciences, Wu Jinzi, stated that this study provides important proof-of-concept data, which will serve as a critical basis for the design of subsequent Phase IIb combination therapy studies for various metabolic diseases, including obesity and metabolic-associated fatty liver disease (MASH) [1]

"作为首项在肥胖受试者中评估脂肪靶向THRβ激动剂与肠促胰素药物联用的研究，我们非常欣喜地看到 脂肪靶向THRβ激动剂ASC47联用肠促胰素治疗产生了显著的减重协同疗效，减重效果相对提升高达 56.2%，并大幅改善了胃肠道耐受性，"歌礼创始人、董事会主席兼首席执行官吴劲梓博士表示，"这项 研究提供了重要的概念验证数据，将为我们后续的包括肥胖症和代谢相关脂肪性肝炎(MASH)等多种代 谢疾病的IIb期联合用药研究设计提供关键依据。" ASC47-103研究(NCT06972992)是一项在美国开展的随机、双盲、安慰剂对照的研究，旨在评估超长效 皮下注射ASC47单次给药与司美格鲁肽(0.5毫克，每周一次，给药四次)联用对比等量(volume-matched) 安慰剂与司美格鲁肽(0.5毫克，每周一次，给药四次)联用在肥胖受试者中的安全性、耐受性及疗效。治 疗期为4周，随访期为6周。该研究在美国开展，共入组了28例肥胖受试者。研究目标包括安全性、耐受 性、药代动力学、ASC47三种不同剂量单次给药(10毫克、30毫克和60毫克)与司美格鲁肽(0.5毫克，每 周一次，给药四次)联用的减重疗效评估。由于治疗周期短(2 ...